Formulary Status
Nationwide, over 80% of patients with prescription drug coverage pay a Tier 1 or Tier 2 copay.1||
Use the free formulary status tool to quickly determine the formulary status of asthma controllers, including SYMBICORT, in your area.
Asthma Patient Support
Encourage your patients to sign up for appointment and refill reminders, air quality and pollen count alerts, and savings on prescription copays.
In combination maintenance therapy for asthma . . .
SYMBICORT exhibited rapid improvement in lung function within 15 minutes3,7*; in addition, most patients felt it begin to work right away8,9†
- SYMBICORT delivered improved asthma control‡ as early as day 1 and over the long term3,5,6
- SYMBICORT exhibited rapid improvement in lung function within 15 minutes3,7*;
in addition, most patients felt it begin to work right away8,9†
- From day 1§, SYMBICORT helps reassure patients that their medication is working
Patients who experienced rapid improvement in lung function were not necessarily the same patients who reported feeling SYMBICORT begin to work right away.
SYMBICORT does NOT replace fast-acting inhalers and should not be used to treat acute symptoms of asthma.
Select a module below to view key information about SYMBICORT
efficacy, safety, dosing, and patient profiles.
Efficacy Data
Review measures of asthma control as demonstrated in clinical studies.
Dosing Information
Learn about dosing SYMBICORT.
Safety Information
Learn about the most common side effects associated with SYMBICORT.
Patient Profiles
Review which types of patients can benefit from SYMBICORT therapy.
*Onset of clinically significant bronchodilation (>15% improvement in forced expiratory volume in 1 second [FEV1]) occurred within 15 minutes (median time).
†Sixty-nine percent of patients reported feeling SYMBICORT begin to work right away during the first week of treatment. Throughout the study, most patients reported feeling it begin to work right away. These data are based on results from a subset of patients >18 years of age (n=442) participating in a 12-week efficacy and safety study for SYMBICORT. Patients were assessed on a weekly basis using the Onset of Effect Questionnaire, administered through an electronic diary to record their responses to 5 statements concerning onset of medication.
‡In pivotal US clinical studies, asthma control was defined as the coprimary efficacy end points of the 12-hour-average postdose FEV1 at week 2 and predose FEV1, averaged over 12 weeks. In addition, measures of asthma control included improvement in peak expiratory flow (PEF) and reduction in asthma symptoms and albuterol rescue use.
§From day 1, maximum improvement in FEV1 occurred within 3 hours and clinically significant improvement was maintained over 12 hours. SYMBICORT improved predose FEV1 and AM and PM PEF and reduced albuterol use and asthma symptoms.
||Individual costs may vary by plan.